Summary
This whitepaper titled 'Optimising biotech funding' outlines the current landscape for biotech companies and the research and development (R&D) strategies they can implement to attract and effectively utilize investment funding. A survey conducted among over 130 biotech executives reveals that 60% anticipate increasing their R&D spending, while only 2% expect to decrease it. However, 32% of respondents identify clinical trials as a significant challenge in bringing new therapies to market, indicating a need for improved collaboration with clinical development partners. The paper discusses various funding sources, including partnerships with large pharmaceutical companies and venture capital, emphasizing the importance of strategic engagement to optimize funding. It also addresses the impact of rising capital costs on operations and highlights best practices for trial design and communication with regulators. The findings suggest that biotechs must balance risk management and innovation to secure and maximize funding opportunities.
